Is Adjuvant Therapy Necessary for Stage IB Gastric Cancer?
Author Information
Author(s): Gu Mingyu MS, Zhao Binghe MS, Sui Changda MS, Wen Minghai MS, Wang Xinxin MD
Primary Institution: The First Medical Center of Chinese PLA General Hospital, Beijing, China
Hypothesis
This study aimed to evaluate the benefit of adjuvant therapy for patients with IB gastric cancer.
Conclusion
Adjuvant therapy did not demonstrate any benefits in terms of tumor recurrence or disease-free survival for IB gastric cancer patients after gastrectomy.
Supporting Evidence
- Patients who received postoperative adjuvant therapy had a longer 5-year overall survival rate (92.9%) compared to those who received surgery alone (86.7%).
- The 5-year disease-free survival did not differ significantly between the two groups.
- Older age was identified as a significant risk factor for tumor recurrence.
Takeaway
The study looked at whether extra treatment after surgery helps people with a certain type of stomach cancer, and it found that it doesn't really help.
Methodology
The study analyzed overall survival and disease-free survival of 510 IB gastric cancer patients after gastrectomy using Kaplan-Meier method and Cox regression analyses.
Potential Biases
There may be imbalances in baseline patient and tumor characteristics between the two groups due to the retrospective design.
Limitations
The study was retrospective and conducted at a single center, which may limit the generalizability of the findings.
Participant Demographics
All patients were of Asian ethnicity, aged between 26 to 80 years, with a mean age of 59.1 years.
Statistical Information
P-Value
P < 0.05
Confidence Interval
95% CI: 0.31–1.78
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website